Long-time and low-dose of CCL7 inhibitor treatment might be a promising alternative strategy to induce tumor dormancy and immune evasion, thus reduce tumor recurrence and prolong the survival of CRC patients. The gene discussed is CCL7; the disease is colorectal carcinoma.